Release Date: May 01, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you discuss the impact of supply dynamics on US revenue growth and the gap between volume and revenue growth? A: Jereme Sylvain, CFO, explained that they exited the quarter with normalized supply levels, which required significant effort. Despite this, they achieved a record new patient quarter, indicating strong performance. The volume growth aligns with a 25% patient increase, consistent with previous trends, and the price-volume gap is closing as expected.
Q: Why did you maintain full-year guidance despite 14% organic growth in Q1, and how does the 15 Day launch affect gross margin guidance? A: Jereme Sylvain, CFO, stated that it's early in the year, and they want to see how the year unfolds before adjusting guidance. The 15 Day launch was included in the original guidance, and its impact on gross margin is expected to be small initially, as it will ramp up over time.
Q: What trends are you seeing in type 2 non-insulin and basal patient utilization and retention? A: Kevin Sayer, CEO, noted strong retention rates in these populations, particularly with reimbursement. Stelo users are also reordering regularly. Jereme Sylvain added that utilization remains strong in covered markets, and Stelo is seeing good uptake among type 2 users.
Q: How exposed is DexCom to a potential recession, and how did you analyze this risk? A: Jereme Sylvain, CFO, explained that they've analyzed their exposure to coverage levels and economic conditions. DexCom's products save costs and are integral to care patterns, positioning them well to weather economic downturns. Kevin Sayer emphasized their value in providing cost-effective health solutions.
Q: Can you provide more details on the international revenue performance and any supply chain impacts? A: Jereme Sylvain, CFO, highlighted pockets of strength in France and Japan due to coverage expansions. While there is some choppiness in international business due to timing of coverage wins, underlying volume demand remains strong. Supply dynamics did not significantly impact international revenue.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.